GlobeNewswire: Orchard Therapeutics (Europe) Limited Contains the last 10 of 157 releaseshttp://www.globenewswire.com/External?Length=42024-03-19T05:32:24ZGlobeNewswirehttp://www.globenewswire.com/External?Length=4newsdesk@globenewswire.com (NewsDesk)https://www.globenewswire.com/news-release/2024/03/18/2848132/0/en/Orchard-Therapeutics-Receives-FDA-Approval-of-Lenmeldy-atidarsagene-autotemcel-the-Only-Therapy-for-Eligible-Children-with-Early-onset-Metachromatic-Leukodystrophy-in-the-U-S.html?f=22&fvtc=4&fvtv=52110Orchard Therapeutics Receives FDA Approval of Lenmeldy™ (atidarsagene autotemcel), the Only Therapy for Eligible Children with Early-onset Metachromatic Leukodystrophy in the U.S.2024-03-18T19:41:13Z<![CDATA[One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years) One-time treatment with Lenmeldy has shown the potential to restore enzymatic function to stop or slow disease progression, with up to 12 years of follow-up (median 6.76 years)]]>https://www.globenewswire.com/news-release/2024/02/05/2823377/0/en/Orchard-Therapeutics-Announces-First-Patient-Randomized-in-Registrational-Trial-of-OTL-203-for-MPS-I-Hurler-Syndrome.html?f=22&fvtc=4&fvtv=52110Orchard Therapeutics Announces First Patient Randomized in Registrational Trial of OTL-203 for MPS-I Hurler Syndrome2024-02-05T12:00:03Z<![CDATA[Gene therapy being developed as a one-time treatment to address the underlying cause of the disease by inserting a functional copy of the human IDUA gene into a patient’s own hematopoietic stem cells]]>https://www.globenewswire.com/news-release/2024/02/02/2822764/0/en/Orchard-Therapeutics-Announces-Multiple-Presentations-at-the-20th-Annual-WORLDSymposium.html?f=22&fvtc=4&fvtv=52110Orchard Therapeutics Announces Multiple Presentations at the 20th Annual WORLDSymposium2024-02-02T12:00:28Z<![CDATA[Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases Three oral presentations and seven posters highlight transformative potential of HSC gene therapy and newborn screening to address severe neurometabolic diseases]]>https://www.globenewswire.com/news-release/2024/01/25/2816563/0/en/Orchard-Therapeutics-Announces-Agreement-with-the-Beneluxa-Consortium-Enabling-Reimbursed-Access-to-Libmeldy.html?f=22&fvtc=4&fvtv=52110Orchard Therapeutics Announces Agreement with the Beneluxa Consortium Enabling Reimbursed Access to Libmeldy2024-01-25T12:00:07Z<![CDATA[BOSTON and LONDON, Jan. 25, 2024 (GLOBE NEWSWIRE) -- Orchard Therapeutics, a global gene therapy leader, today announced the company has reached an agreement with the Beneluxa Initiative on Pharmaceutical Policy (Beneluxa) enabling reimbursed access to Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, approved for the treatment of early-onset metachromatic leukodystrophy (MLD). The agreement covers several member countries, including Belgium, The Netherlands, and Ireland. It follows similar arrangements made with reimbursement authorities in the United Kingdom (UK), Italy, Germany, Sweden, Iceland, Finland and Norway, and is a key component of the company’s geographic expansion plans.]]>https://www.globenewswire.com/news-release/2024/01/24/2814887/0/en/Kyowa-Kirin-successfully-completes-acquisition-of-Orchard-Therapeutics-a-global-gene-therapy-leader-for-rare-diseases.html?f=22&fvtc=4&fvtv=52110Kyowa Kirin successfully completes acquisition of Orchard Therapeutics, a global gene therapy leader for rare diseases2024-01-24T10:00:00Z<![CDATA[Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps to resource ongoing and future launches of Libmeldy® (atidarsagene autotemcel) in early-onset MLD Acquisition enriches Kyowa Kirin’s portfolio, enables the development of numerous promising candidates with a clinically differentiated platform, and helps to resource ongoing and future launches of Libmeldy® (atidarsagene autotemcel) in early-onset MLD]]>https://www.globenewswire.com/news-release/2023/12/11/2793712/0/en/Orchard-Therapeutics-Receives-Swissmedic-Approval-for-Libmeldy-in-Early-onset-MLD.html?f=22&fvtc=4&fvtv=52110Orchard Therapeutics Receives Swissmedic Approval for Libmeldy in Early-onset MLD2023-12-11T12:00:17Z<![CDATA[BOSTON and LONDON, Dec. 11, 2023 (GLOBE NEWSWIRE) -- Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced the Swiss Agency for Therapeutic Products (Swissmedic) has approved Libmeldy® (atidarsagene autotemcel), a hematopoietic stem cell (HSC) gene therapy, for the treatment of early-onset metachromatic leukodystrophy (MLD).]]>https://www.globenewswire.com/news-release/2023/11/30/2788476/0/en/Orchard-Therapeutics-Receives-U-S-FDA-Fast-Track-Designation-for-OTL-203-in-MPS-IH.html?f=22&fvtc=4&fvtv=52110Orchard Therapeutics Receives U.S. FDA Fast Track Designation for OTL-203 in MPS-IH2023-11-30T12:00:16Z<![CDATA[Previously reported results from ongoing proof-of-concept study showed extensive metabolic correction, continued cognitive, motor, and physical development, as well as early improvements in skeletal health]]>https://www.globenewswire.com/news-release/2023/11/13/2778891/0/en/Orchard-Therapeutics-Reports-Third-Quarter-2023-Financial-Results-and-Highlights-Recent-Business-Accomplishments.html?f=22&fvtc=4&fvtv=52110Orchard Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Business Accomplishments2023-11-13T12:00:00Z<![CDATA[Reported $5.6 million in quarterly Libmeldy net revenue and $12.7 million year-to-date]]>https://www.globenewswire.com/news-release/2023/10/26/2767345/0/en/Orchard-Therapeutics-Announces-Presentation-of-Additional-Positive-Data-from-Proof-of-concept-Study-of-OTL-203-in-MPS-IH-at-ESGCT-2023.html?f=22&fvtc=4&fvtv=52110Orchard Therapeutics Announces Presentation of Additional Positive Data from Proof-of-concept Study of OTL-203 in MPS-IH at ESGCT 20232023-10-26T11:00:00Z<![CDATA[New clinical data beyond previously reported neurological and skeletal results demonstrate favorable outcomes for multiple disease manifestations not effectively addressed by the current standard of care New clinical data beyond previously reported neurological and skeletal results demonstrate favorable outcomes for multiple disease manifestations not effectively addressed by the current standard of care]]>https://www.globenewswire.com/news-release/2023/10/24/2765468/0/en/Orchard-Therapeutics-Announces-Multiple-Presentations-at-ESGCT-2023.html?f=22&fvtc=4&fvtv=52110Orchard Therapeutics Announces Multiple Presentations at ESGCT 20232023-10-24T11:00:49Z<![CDATA[Eight presentations highlight the differentiated profile and broad applicability of the company’s HSC gene therapy platform]]>